Get the Stockscreener App
1.73
8.81%
0.14
After Hours:
1.74
0.01
+0.58%
Theriva Biologics Inc stock is traded at $1.73, with a volume of 169.00K.
It is up +8.81% in the last 24 hours and up +36.22% over the past month.
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11. It has collaborations with The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.
See More
Previous Close:
$1.59
Open:
$1.6
24h Volume:
169.00K
Relative Volume:
0.06
Market Cap:
$4.81M
Revenue:
-
Net Income/Loss:
$-18.35M
P/E Ratio:
-1.4914
EPS:
-1.16
Net Cash Flow:
$-19.20M
1W Performance:
+15.33%
1M Performance:
+36.22%
6M Performance:
-98.84%
1Y Performance:
-99.38%
1-Day Range:
$1.60
$1.7896
1-Week Range:
$1.50
$1.7896
52-Week Range:
$1.14
$427.81
Theriva Biologics Inc Stock (TOVX) Company Profile
Name
Theriva Biologics Inc
Sector
Industry
Phone
301 417 4364
Address
9605 Medical Center Drive, Suite 270, Rockville
Compare TOVX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TOVX
Theriva Biologics Inc
|
1.73 | 4.81M | 0 | -18.35M | -19.20M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
402.49 | 103.65B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.26 | 78.71B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
645.37 | 38.59B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
233.15 | 30.07B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.21 | 28.82B | 3.30B | -501.07M | 1.03B | -2.1146 |
Theriva Biologics Inc Stock (TOVX) Latest News
US Stocks To Open Higher On Shortened Trading Day: Santa Claus Rally Period Officially Begins, Says Analyst - Benzinga
Synthetic Biologics stock hits 52-week low at $1.21 - Investing.com India
Synthetic Biologics stock hits 52-week low at $1.21 By Investing.com - Investing.com UK
Theriva Biologics outlines Phase 3 study for cancer drug By Investing.com - Investing.com Canada
Theriva™ Biologics Announces U.S. FDA Guidance on Design of - GlobeNewswire
Theriva Biologics Gets FDA Guidance on VCN-01 Phase 3 Trial Design for Pancreatic Cancer Treatment - StockTitan
Synthetic Biologics stock hits 52-week low at $1.24 By Investing.com - Investing.com South Africa
Synthetic Biologics stock hits 52-week low at $1.24 - Investing.com
Maxim Group Has Lowered Expectations for Theriva Biologics (NYSEAMERICAN:TOVX) Stock Price - Defense World
Theriva Biologics Highlights Key Achievements in Q3 2024 - TipRanks
Theriva Biologics: Q3 Earnings Snapshot - Houston Chronicle
Theriva™ Biologics Reports Third Quarter 2024 Operational Highlights and Financial Results - GlobeNewswire
Theriva Biologics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
What's Going On With Theriva Biologics Stock Friday? - MSN
Theriva Biologics Expands Stock Plans and Share Authority - TipRanks
Theriva Biologics Selected as Finalist in International Competition for Merck KGaA's EMEA Advance Biotech Grant - The Manila Times
Theriva Biologics gains EU orphan drug status for eye cancer treatment - Investing.com
Theriva Biologics Announces Orphan Medicinal Product - GlobeNewswire
Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma - StockTitan
Check out these key findings about Theriva Biologics Inc (TOVX) - SETE News
Theriva Biologics Inc: A Comprehensive Look at the Stock’s Ups and Downs - The InvestChronicle
Was Theriva Biologics Inc (TOVX)’s session last reading good? - US Post News
Market cap of Theriva Biologics Inc [TOVX] reaches 4.06M – now what? - The DBT News
Closing Figures: Theriva Biologics Inc (TOVX)’s Positive Finish at 1.79, Up 44.35 - The Dwinnex
Theriva reports progress in phase 1b/2a trial of SYN-004 By Investing.com - Investing.com South Africa
Synthetic Biologics stock plunges to 52-week low of $1.24 By Investing.com - Investing.com Australia
Theriva reports progress in phase 1b/2a trial of SYN-004 - Investing.com Australia
OMER Stock Falls 5.35% Amid Mixed Institutional Ratings - GuruFocus.com
Halozyme (HALO) Stock Surges Amid Positive Earnings and Analyst Ratings - GuruFocus.com
Crude Oil Jumps Over 4%; US Services PMI Revised Lower - Benzinga
Nano-Cap Theriva Biologics' Investigational Drug For Transplant-Related Complication Shows Safety In Bone Marrow Transplant Patients - Benzinga
Theriva Biologics up on positive DSMC review in SYN-004 trial for transplant recipients - Seeking Alpha
Theriva Biologics Advances SYN-004 in Clinical Trial - TipRanks
Theriva™ Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients - The Manila Times
Theriva™ Biologics Announces Positive Outcome of Data and - GlobeNewswire
Synthetic Biologics stock plunges to 52-week low of $1.24 - Investing.com India
Was anything negative for Theriva Biologics Inc (TOVX) stock last session? - US Post News
Why Establishment Labs Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket - MSN
Theriva Biologics dips 11%, prices 2.5M equity offering - MSN
Theriva Biologics Announces Pricing of $2.5 Million Public Offering - StockTitan
Theriva Biologics Inc (TOVX) Stock: From Low to High in 52 Weeks - The InvestChronicle
Understanding TOVX stock ratios for better investment decisions - US Post News
Theriva Biologics Inc Stock (TOVX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.27%
0.26%
Cap:
|
Volume (24h):